Arteriosclerosis, Thrombosis, and Vascular Biology. 1997;17:2257-2263
© 1997 American Heart Association, Inc.
Articles |
Expression of Phospholipase A2 Isoforms in Human Normal and Atherosclerotic Arterial Wall
From the Department of Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm (L.S.E., P.L, H-E.C.); and the Departments of Surgery (A.D., U.H.) and Rheumatology (J.F.), Karolinska Hospital, Stockholm, Sweden.
Correspondence to Liselotte Schäfer Elinder, King Gustaf V's Research Institute, Department of Medicine, Karolinska Hospital, 17176 Stockholm, Sweden.
Abstract LDL particles must be modified in the arterial wall to be taken up by macrophages at an excessive rate, leading to foam cell formation. Phospholipase A2 (PLA2) has been shown to modify LDL particles in vitro by degrading its phospholipids, resulting in enhanced uptake by macrophages. Reaction products of PLA2 are lysophospholipids and nonesterified fatty acids (mainly arachidonic acid), which are precursors of potent inflammatory mediators and which have been found in atherosclerotic regions of the arterial wall. To elucidate the expression of PLA2 in normal and diseased arteries, frozen tissue sections of human nonatherosclerotic mesenteric artery and carotid plaques were examined by immunohistochemistry using specific antibodies against secretory PLA2 types I and II and cytosolic PLA2 (85 kd). Secretory PLA2 type I was not detected. High expression of secretory PLA2 type II was found throughout the media in both normal and atherosclerotic artery specimens, in which smooth muscle cells dominated. Cytosolic PLA2 was found exclusively in diseased artery, mainly in the intima in regions with an inflammatory infiltrate consisting of macrophages and smooth muscle cells. Furthermore, both normal and atherosclerotic artery possessed substantial PLA2 activity. It is suggested that secretory PLA2 type II could play an important role in early atherogenesis because it is present in the preatherosclerotic arterial wall, where it may lead to LDL modification, foam cell formation, and activation of immune mechanisms.
Key Words: phospholipase A2 • atherosclerosis • arterial wall
This article has been cited by other articles:
 |
|
 |
|
  A. Asai, F. Okajima, K. Nakagawa, D. Ibusuki, K. Tanimura, Y. Nakajima, M. Nagao, M. Sudo, T. Harada, T. Miyazawa, et al. Phosphatidylcholine hydroperoxide-induced THP-1 cell adhesion to intracellular adhesion molecule-1 J. Lipid Res., May 1, 2009; 50(5): 957 - 965. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. C. Tsoukatos, I. Brocheriou, V. Moussis, C. P. Panopoulou, E. D. Christofidou, S. Koussissis, S. Sismanidis, E. Ninio, and S. Siminelakis Platelet-activating factor acetylhydrolase and transacetylase activities in human aorta and mammary artery J. Lipid Res., October 1, 2008; 49(10): 2240 - 2249. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. T.E. Wootton, N. L. Arora, F. Drenos, S. R. Thompson, J. A. Cooper, J. W. Stephens, S. J. Hurel, E. Hurt-Camejo, O. Wiklund, S. E. Humphries, et al. Tagging SNP haplotype analysis of the secretory PLA2-V gene, PLA2G5, shows strong association with LDL and oxLDL levels, suggesting functional distinction from sPLA2-IIA: results from the UDACS study Hum. Mol. Genet., June 15, 2007; 16(12): 1437 - 1444. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Mallat, J. Benessiano, T. Simon, S. Ederhy, C. Sebella-Arguelles, A. Cohen, V. Huart, N. J. Wareham, R. Luben, K.-T. Khaw, et al. Circulating Secretory Phospholipase A2 Activity and Risk of Incident Coronary Events in Healthy Men and Women: The EPIC-NORFOLK Study Arterioscler Thromb Vasc Biol, May 1, 2007; 27(5): 1177 - 1183. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Rosengren, H. Peilot, M. Umaerus, A.-C. Jonsson-Rylander, L. Mattsson-Hulten, C. Hallberg, P. Cronet, M. Rodriguez-Lee, and E. Hurt-Camejo Secretory Phospholipase A2 Group V: Lesion Distribution, Activation by Arterial Proteoglycans, and Induction in Aorta by a Western Diet Arterioscler Thromb Vasc Biol, July 1, 2006; 26(7): 1579 - 1585. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. T.E. Wootton, F. Drenos, J. A. Cooper, S. R. Thompson, J. W. Stephens, E. Hurt-Camejo, O. Wiklund, S. E. Humphries, and P. J. Talmud Tagging-SNP haplotype analysis of the secretory PLA2IIa gene PLA2G2A shows strong association with serum levels of sPLA2IIa: results from the UDACS study Hum. Mol. Genet., January 15, 2006; 15(2): 355 - 361. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Mallat, Ph. G. Steg, J. Benessiano, M.-L. Tanguy, K. A. Fox, J.-P. Collet, O. H. Dabbous, P. Henry, K. F. Carruthers, A. Dauphin, et al. Circulating Secretory Phospholipase A2 Activity Predicts Recurrent Events in Patients With Severe Acute Coronary Syndromes J. Am. Coll. Cardiol., October 4, 2005; 46(7): 1249 - 1257. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Frostegard Atherosclerosis in Patients With Autoimmune Disorders Arterioscler Thromb Vasc Biol, September 1, 2005; 25(9): 1776 - 1785. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. J. F. Tietge, D. Pratico, T. Ding, C. D. Funk, R. B. Hildebrand, T. Van Berkel, and M. Van Eck Macrophage-specific expression of group IIA sPLA2 results in accelerated atherogenesis by increasing oxidative stress J. Lipid Res., August 1, 2005; 46(8): 1604 - 1614. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Boekholdt, T. T. Keller, N. J. Wareham, R. Luben, S. A. Bingham, N. E. Day, M. S. Sandhu, J. W. Jukema, J. J.P. Kastelein, C. E. Hack, et al. Serum Levels of Type II Secretory Phospholipase A2 and the Risk of Future Coronary Artery Disease in Apparently Healthy Men and Women: The EPIC-Norfolk Prospective Population Study Arterioscler Thromb Vasc Biol, April 1, 2005; 25(4): 839 - 846. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. I. Ghesquiere, M. J. J. Gijbels, M. Anthonsen, P. J. J. van Gorp, I. van der Made, B. Johansen, M. H. Hofker, and M. P. J. de Winther Macrophage-specific overexpression of group IIa sPLA2 increases atherosclerosis and enhances collagen deposition J. Lipid Res., February 1, 2005; 46(2): 201 - 210. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Iribarren, M. D. Gross, J. A. Darbinian, D. R. Jacobs Jr, S. Sidney, and C. M. Loria Association of Lipoprotein-Associated Phospholipase A2 Mass and Activity With Calcified Coronary Plaque in Young Adults: The CARDIA Study Arterioscler Thromb Vasc Biol, January 1, 2005; 25(1): 216 - 221. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Cederholm, E. Svenungsson, K. Jensen-Urstad, C. Trollmo, A.-K. Ulfgren, J. Swedenborg, G.-Z. Fei, and J. Frostegard Decreased Binding of Annexin V to Endothelial Cells: A Potential Mechanism in Atherothrombosis of Patients With Systemic Lupus Erythematosus Arterioscler Thromb Vasc Biol, January 1, 2005; 25(1): 198 - 203. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. R. Wooton-Kee, B. B. Boyanovsky, M. S. Nasser, W. J.S. de Villiers, and N. R. Webb Group V sPLA2 Hydrolysis of Low-Density Lipoprotein Results in Spontaneous Particle Aggregation and Promotes Macrophage Foam Cell Formation Arterioscler Thromb Vasc Biol, April 1, 2004; 24(4): 762 - 767. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. W.M Niessen, P. A.J Krijnen, C. A Visser, C. J.L.M Meijer, and C Erik Hack Type II secretory phospholipase A2 in cardiovascular disease: a mediator in atherosclerosis and ischemic damage to cardiomyocytes? Cardiovasc Res, October 15, 2003; 60(1): 68 - 77. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P.-Y. Liu, Y.-H. Li, W.-C. Tsai, T.-H. Chao, L.-M. Tsai, H.-L. Wu, and J.-H. Chen Prognostic value and the changes of plasma levels of secretory type II phospholipase A2 in patients with coronary artery disease undergoing percutaneous coronary intervention Eur. Heart J., October 2, 2003; 24(20): 1824 - 1832. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Akiba, Y. Yoneda, S. Ohno, M. Nemoto, and T. Sato Oxidized LDL activates phospholipase A2 to supply fatty acids required for cholesterol esterification J. Lipid Res., September 1, 2003; 44(9): 1676 - 1685. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. R. Webb, M. A. Bostrom, S. J. Szilvassy, D. R. van der Westhuyzen, A. Daugherty, and F. C. de Beer Macrophage-Expressed Group IIA Secretory Phospholipase A2 Increases Atherosclerotic Lesion Formation in LDL Receptor-Deficient Mice Arterioscler Thromb Vasc Biol, February 1, 2003; 23(2): 263 - 268. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Y. Hui and P. N. Howles Carboxyl ester lipase: structure-function relationship and physiological role in lipoprotein metabolism and atherosclerosis J. Lipid Res., December 1, 2002; 43(12): 2017 - 2030. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Hanasaki, K. Yamada, S. Yamamoto, Y. Ishimoto, A. Saiga, T. Ono, M. Ikeda, M. Notoya, S. Kamitani, and H. Arita Potent Modification of Low Density Lipoprotein by Group X Secretory Phospholipase A2 Is Linked to Macrophage Foam Cell Formation J. Biol. Chem., August 2, 2002; 277(32): 29116 - 29124. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Hurt-Camejo, G. Camejo, H. Peilot, K. Oorni, and P. Kovanen Phospholipase A2 in Vascular Disease Circ. Res., August 17, 2001; 89(4): 298 - 304. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Couturier, V. Antonio, A. Brouillet, G. Bereziat, M. Raymondjean, and M. Andreani Protein Kinase A-Dependent Stimulation of Rat Type II Secreted Phospholipase A2 Gene Transcription Involves C/EBP-{beta} and -{{delta}} in Vascular Smooth Muscle Cells Arterioscler Thromb Vasc Biol, December 1, 2000; 20(12): 2559 - 2565. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. J. Packard, D. S.J. O'Reilly, M. J. Caslake, A. D. McMahon, I. Ford, J. Cooney, C. H. Macphee, K. E. Suckling, M. Krishna, F. E. Wilkinson, et al. Lipoprotein-Associated Phospholipase A2 as an Independent Predictor of Coronary Heart Disease N. Engl. J. Med., October 19, 2000; 343(16): 1148 - 1155. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Kugiyama, Y. Ota, H. Kawano, H. Soejima, H. Ogawa, S. Sugiyama, H. Doi, and H. Yasue Increase in plasma levels of secretory type II phospholipase A2 in patients with coronary spastic angina Cardiovasc Res, July 1, 2000; 47(1): 159 - 165. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. W. Anthonsen, D. Stengel, D. Hourton, E. Ninio, and B. Johansen Mildly Oxidized LDL Induces Expression of Group IIa Secretory Phospholipase A2 in Human Monocyte-Derived Macrophages Arterioscler Thromb Vasc Biol, May 1, 2000; 20(5): 1276 - 1282. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. MANZI, M. C. M WASKO, and S. MANZI Inflammation-mediated rheumatic diseases and atherosclerosis Ann Rheum Dis, May 1, 2000; 59(5): 321 - 325. [Full Text]
|
|
|
|
 |
|
 S. Manzi Systemic lupus erythematosus: a model for atherogenesis? Rheumatology, April 1, 2000; 39(4): 353 - 359. [Full Text] [PDF]
|
|
|
|
|
|
P. T. Kovanen and M. O. Pentikainen Secretory Group II Phospholipase A2 : A Newly Recognized Acute-Phase Reactant With a Role in Atherogenesis Circ. Res., March 31, 2000; 86(6): 610 - 612. [Full Text] [PDF]
|
|
|
|
|
|
M. Menschikowski, A. Rosner-Schiering, R. Eckey, E. Mueller, R. Koch, and W. Jaross Expression of Secretory Group IIA Phospholipase A2 in Relation to the Presence of Microbial Agents, Macrophage Infiltrates, and Transcripts of Proinflammatory Cytokines in Human Aortic Tissues Arterioscler Thromb Vasc Biol, March 1, 2000; 20(3): 751 - 762. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Hakkinen, J. S. Luoma, M. O. Hiltunen, C. H. Macphee, K. J. Milliner, L. Patel, S. Q. Rice, D. G. Tew, K. Karkola, and S. Yla-Herttuala Lipoprotein-Associated Phospholipase A2, Platelet-Activating Factor Acetylhydrolase, Is Expressed by Macrophages in Human and Rabbit Atherosclerotic Lesions Arterioscler Thromb Vasc Biol, December 1, 1999; 19(12): 2909 - 2917. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Kugiyama, Y. Ota, K. Takazoe, Y. Moriyama, H. Kawano, Y. Miyao, T. Sakamoto, H. Soejima, H. Ogawa, H. Doi, et al. Circulating Levels of Secretory Type II Phospholipase A2 Predict Coronary Events in Patients with Coronary Artery Disease Circulation, September 21, 1999; 100(12): 1280 - 1284. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Sartipy, G. Camejo, L. Svensson, and E. Hurt-Camejo Phospholipase A2 Modification of Low Density Lipoproteins Forms Small High Density Particles with Increased Affinity for Proteoglycans and Glycosaminoglycans J. Biol. Chem., September 3, 1999; 274(36): 25913 - 25920. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Couturier, A. Brouillet, C. Couriaud, K. Koumanov, G. Bereziat, and M. Andreani Interleukin 1beta Induces Type II-secreted Phospholipase A2 Gene in Vascular Smooth Muscle Cells by a Nuclear Factor kappa B and Peroxisome Proliferator-activated Receptor-mediated Process J. Biol. Chem., August 13, 1999; 274(33): 23085 - 23093. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J George, D Harats, B Gilburd, Y Levy, P Langevitz, and Y Shoenfeld Atherosclerosis-related markers in systemic lupus erythematosus patients: The role of humoral immunity in enhanced atherogenesis Lupus, March 1, 1999; 8(3): 220 - 226. [Abstract] [PDF]
|
|
|
|
|
|
W. Pruzanski, E. Stefanski, F. C. de Beer, M. C. de Beer, P. Vadas, A. Ravandi, and A. Kuksis Lipoproteins are substrates for human secretory group IIA phospholipase A2: preferential hydrolysis of acute phase HDL J. Lipid Res., November 1, 1998; 39(11): 2150 - 2160. [Abstract] [Full Text]
|
|
|
|
|
|
R. Wu, Y. H. Huang, L. S. Elinder, and J. Frostegard Lysophosphatidylcholine Is Involved in the Antigenicity of Oxidized LDL Arterioscler Thromb Vasc Biol, April 1, 1998; 18(4): 626 - 630. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Peilot, B. Rosengren, G. Bondjers, and E. Hurt-Camejo Interferon-gamma Induces Secretory Group IIA Phospholipase A2 in Human Arterial Smooth Muscle Cells. INVOLVEMENT OF CELL DIFFERENTIATION, STAT-3 ACTIVATION, AND MODULATION BY OTHER CYTOKINES J. Biol. Chem., July 21, 2000; 275(30): 22895 - 22904. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Ribardo, S. E. Crowe, K. R. Kuhl, J. W. Peterson, and A. K. Chopra Prostaglandin Levels in Stimulated Macrophages Are Controlled by Phospholipase A2-activating Protein and by Activation of Phospholipase C and D J. Biol. Chem., February 16, 2001; 276(8): 5467 - 5475. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Hernandez, L. Fuentes, F. J. Fernandez Aviles, M. S. Crespo, and M. L. Nieto Secretory Phospholipase A2 Elicits Proinflammatory Changes and Upregulates the Surface Expression of Fas Ligand in Monocytic Cells: Potential Relevance for Atherogenesis Circ. Res., January 11, 2002; 90(1): 38 - 45. [Abstract] [Full Text] [PDF]
|
|